Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily
The investigators will investigate the efficacy and safety of different β -blockers, as well as heart rate variability, in STEMI patients undergoing primary PCI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
1,200
Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
Change in LVEDV from baseline
The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) post-PCI.
Time frame: 1 to 5 years
Major adverse cardiovascular events (MACE)
Time frame: 1 to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.